KLF11 promotes the progression of glioma via regulating Holliday junction recognition protein. (11th April 2022)

• Record Type: Journal Article
• Authors: Li, Jian; Wang, Chunhong; Cheng, Rui; Su, Haiyang; Wang, Lijun; Ji, Lei; Ji, Hongming
• Is Part Of: Cell biology international. Volume 46:Number 7(2022)
• Page Start: 1144
• Page End: 1155
• Publication Date: 2022-04-11
• Subjects: biomarker -- glioma -- HJURP -- KLF11 -- prognosis; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.11795
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: Understanding the molecular mechanism of glioma is very important for the diagnosis and treatment of glioma. Recently, a new study illustrated that KLF11 could be a potential prognostic and diagnostic biomarker in glioma, but the critical role is not illustrated. In this study, we found that KLF11 was highly expressed in glioma cancer tissues and cells, and KLF11 high expression of glioblastoma (GBM) and lower‐grade glioma (LGG) were correlated with poorer overall survival and disease‐free survival percentages. KLF11 knockdown inhibited glioma cell proliferation and migration, while KLF11 overexpression enhanced cell proliferation and migration. In vivo, knockdown of KLF11 reduced the tumor size of glioma. With regard to the molecular regulatory mechanism, we clarified that the Holliday junction recognition protein (HJURP) was positively regulated by KLF11. Meanwhile, we demonstrated that HJURP knockdown also inhibited glioma carcinoma progression. Overexpression of HJURP rescued the suppressed proliferation and migration function of glioma cells with depletion of KLF11. Therefore, our study demonstrated the function of KLF11 in glioma and showed KLF11 and HJURP could be prognostic and diagnostic markers in glioma, which provides a new insight of glioma therapy.